Breaking AI & Tech News Analyzed

The Proposed Pay Scheme The chief executive of Arm is in line for a pay package that would make him a billionaire if he hits targets to turn the British microchip giant into the UK's first trillion-dollar company. Arm, which is listed in New York but retains its global headquarters in Cambridge, has proposed a pay scheme for Rene Haas in which he will receive generous annual share awards plus a maximum bonus of $800m if he can hit certain 'exceptional growth metrics'. The Targets In the proposed bonus, or 'value creation plan' for Haas, 63, he will be awarded 425,000 shares if he can hit targets. The first target is a trillion-dollar valuation by 2029, reaching $1.25trn the following year and £2trn by the end of March 2031. The Financial Impact The payout would be one of the biggest ever awarded by a British company. Assuming the policy is approved and the targets are hit, Haas is in line to make well over $1bn in total by 2031. Maximum bonus: $800m Annual award of shares: up to 200% of salary Targets: $1 trillion valuation by 2029, $1.25trn by 2030, and £2trn by 2031 The Industry Impact The eye-watering market capitalisation-based pay schemes increasingly being offered by US companies dwarf the level of rewards at UK businesses. This deal highlights the competitive nature of executive remuneration in the global technology industry. The Future Outlook Haas, who is pushing Arm from its core strategy of providing architecture for microchips in smartphones into developing chips for AI datacentres, has predicted that this change of tack could increase Arm's revenues fivefold.

The Lead: Arsenal's Mixed Season of Triumph and HeartbreakArsenal's 2025-2026 season encapsulated both remarkable achievement and painful disappointment. While the club secured its first Premier League title since 2004 under Mikel Arteta's leadership, they also endured the agony of losing two finals, most recently the Champions League final against PSG on penalties. This duality defined a season that stretched players to their physical and mental limits.The Season Marathon: Physical and Mental Toll on PlayersDeclan Rice emphasized the extraordinary demands of the season, noting that Arsenal's journey began in July with a pre-season match in Singapore and concluded with their 63rd game across all competitions. The midfielder highlighted the particularly grueling stretch from October onward, when the team faced three matches per week. Rice himself played in 55 of Arsenal's matches while battling through a persistent injury that left him operating at '70%' fitness for 'quite a while,' according to Thomas Tuchel.The Final Performance: Tactical Execution and Individual FlawsIn the Champions League final, Arsenal demonstrated their tactical discipline under Arteta's guidance. After Kai Havertz's early goal, the team effectively neutralized PSG's formidable attack until Cristhian Mosquera conceded a penalty that led to Ousmane Dembélé's equalizer. However, the match exposed several persistent issues: Arsenal's pass completion rate was a concerning 69% compared to PSG's 91%, and they made only 196 successful passes to PSG's 806. Individual attacking statistics were equally troubling, with Bukayo Saka completing just four passes and Martin Ødegaard touching the ball only 12 times.The Penalty Shootout: Misses and Mental FortitudeThe final's conclusion on penalties highlighted both Arsenal's resilience and their remaining vulnerabilities. Gabriel Magalhães missed the decisive fifth penalty, continuing a pattern that saw him miss in a pre-season shootout against Villarreal. Eberechi Eze's penalty technique, which had previously failed him in Crystal Palace's Community Shield victory, resurfaced with identical results against Arsenal. Despite these setbacks, Declan Rice's successful conversion in round three symbolized the team's character and determination throughout the match.Arteta's Evolution: From 'Mikelito' to Respected ManagerThe final showcased Mikel Arteta's growth as a manager, particularly in how his players executed the gameplan against PSG. Luis Enrique's affectionate yet potentially patronizing use of Arteta's old nickname 'Mikelito'—a reference to his time as a young hopeful at Barcelona—underscored the respect Arteta has earned. The Arsenal manager's ability to nullify Europe's most feared attack demonstrated his tactical acumen, even as the team's lack of precision in final passes revealed areas for continued development.The Road Ahead: Building on ProgressArsenal's season, while ending in Champions League final heartbreak, represents significant progress under Arteta. The combination of Premier League triumph and European final appearance establishes a foundation for future success. The physical and mental resilience demonstrated throughout the season, particularly in the face of such a demanding fixture schedule, suggests that the team is building the necessary characteristics to compete at the highest level consistently. As Rice noted, the experience gained from this grueling campaign will fuel their ambitions in seasons to come.

Iga Swiatek's bid for a fifth Roland Garros title ended abruptly on her 25th birthday, as she fell 7‑5, 6‑1 to Ukraine's 15th‑seed Marta Kostyuk in the round of 16. Swiatek’s Fifth Title Quest Ends in the Round of 16 The former champion entered Paris as the clear favorite, but Kostyuk's aggressive baseline play and mental composure proved decisive. After trading early breaks, Kostyuk seized a crucial 11th‑game break to close the first set, then dominated the second with a 6‑1 surge. Numbers That Reveal the Scale of the Upset Scoreline: 7‑5, 6‑1 in favor of Kostyuk Seedings: Swiatek (4) vs. Kostyuk (15) Kostyuk’s 2026 clay record: 15‑0 entering the match Swiatek’s birthday: May 31, 2001 (turned 25) Other recent upsets: Jannik Sinner, Novak Djokovic, Coco Gauff, and China’s Wang Xinyu all exited within three days Implications for the Women’s Grand Slam Landscape Swiatek’s departure elevates world No.1 Aryna Sabalenka to the clear favorite for her first French Open crown. It also signals a shift toward greater depth on the WTA tour, where lower‑seeded players like Kostyuk and veteran Sorana Cirstea—who reached her first Roland Garros quarter‑final in 17 years—are capable of toppling the elite. What to Expect in the Remaining French Open Rounds Kostyuk will face either 7th‑seed Elina Svitolina or 11th‑seed Belinda Bencic in the quarter‑finals, while Sabalenka is expected to navigate a draw that now lacks its former dominant force. The tournament is likely to produce at least one more surprise, as the momentum gained by emerging clay‑court specialists continues to challenge the traditional hierarchy.

Iga Swiatek's Unhappy Birthday at French Open Iga Swiatek's 25th birthday celebrations turned sour at the French Open on Sunday as the former champion lost 7-5, 6-1 in the fourth round to the Ukrainian 15th seed Marta Kostyuk, her challenge for a fifth title ending just when she had looked to be rediscovering her rhythm. The Match Turning Point There was little to separate the duo in the early exchanges as they twice traded breaks, before Kostyuk came up with a tight hold in the 11th game and raised her level at the end to claim the opening set with a backhand crosscourt winner. Kostyuk's Historic Win It was the first time that Kostyuk had taken a set off the third-seeded Pole after three straight-set defeats in their previous meetings, and she sensed a big upset when she went ahead 3-1 in the next set after a battling effort. The Impact on Swiatek's Title Hopes The Rouen and Madrid champion held her nerve from there to take her record on clay this season to 15-0, and book a meeting with the seventh-seeded Ukrainian Elina Svitolina or the 11th-seeded Swiss Belinda Bencic in the next round at Roland Garros. What's Next Tumaini Carayol’s report to follow

Day eight of the 2026 French Open at Roland‑Garros kicked off with a marquee clash between four‑time champion Iga Swiatek and rising talent Marta Kostyuk, alongside a host of other high‑stakes matches that could reshape the second week.Swiatek Takes on Kostyuk in a Potential ClassicThe opening encounter pits the defending champion, seeded #1, against the Ukrainian prodigy, seeded #12. Both players have displayed a blend of power and finesse throughout the tournament, setting the stage for a match that could define the women's title race.Seedings and Rankings Highlight the StakesIga Swiatek – World No. 1, French Open champion 2022‑2025.Marta Kostyuk – World No. 12, semifinalist in 2025.Jil Teichmann vs Mirra Andreeva – both ranked inside the top 30.Andrey Rublev – former top‑5, seeking a deep run after early exits by Djokovic, Alcaraz and Sinner.Implications for the Women’s Draw and Emerging ContendersA Swiatek victory would reinforce her dominance and likely secure a top‑seeded path to the final. A Kostyuk upset could open the draw for players like Elina Svitolina and Belinda Bencic, who are already positioned as dark horses.What to Watch in the Remainder of Day EightHow qualifier Wang Xiyu adapts to the clay after a surprise run.The performance of Jodár against Pedro Carreño Busta (men’s match).Whether Andrey Rublev can capitalize on the absence of the “Big Three”.

Martin Parr—renowned for documenting the idiosyncratic corners of British life—was given a farewell as unconventional as his work. On 31 May 2026, the chapel at Woodlands Memorial Garden near Bristol hosted a colourful country‑fete celebration, complete with music from The Girl from Ipanema, bunting, and a bus that famously got stuck in the mud. The Fete‑Style Send‑off That Defied Funeral Norms The ceremony blended solemnity with the photographer’s trademark humour. Guests were served cling‑film‑wrapped sandwiches, cupcakes with tiny Union Jack flags, and a tombola of unwanted Christmas gifts—an homage to the annual auction the Parr family used to run. The event was organised with help from the Martin Parr Foundation and featured a collaborative food installation by Ellen Parr (the photographer’s daughter) and set‑designer Alice Hodge. Key Players and Personal Touches Grayson Perry – celebrated artist and longtime friend, described the service as “tasteful, pared‑back and very touching.” Sophie Green – photographer who documented the funeral, linking the occasion to her “Death Rituals” project. Helô Pinheiro – the original “Girl from Ipanema,” whose music featured in the playlist. Family – Susie Parr, Martin’s wife of 40 years, confirmed he would have wanted the ceremony photographed. Why Parr’s Funeral Resonates in the Photography Community Parr spent half a century turning the mundane into visual satire; his own send‑off mirrored that ethos. By inviting a photographer to capture the event, the family highlighted a long‑standing taboo—funeral photography—while honoring Parr’s fascination with death rituals, evident in his 1993 Indonesian funeral series and the 2013 Photographers’ Gallery exhibition. What This Means for Future Death‑Ritual Documentation Sophie Green’s involvement underscores a growing interest in recording funerary moments as cultural artifacts. She notes that, on average, she photographs five funerals a year, a figure that may rise as artists and families seek more personalized memorials. The blend of celebration and documentation at Parr’s funeral could inspire a new genre where mourning and festivity coexist, reshaping how societies view death. Looking Ahead: From Taboo to Tribute As the conversation around death becomes more open—accelerated by pandemic‑era restrictions—events like Parr’s funeral suggest a shift toward inclusive, creative rituals. Institutions such as the Martin Parr Foundation may increasingly support projects that capture these moments, offering both solace to grieving families and valuable visual records for future generations.

The Collapse of the FavoritesDefending champion Coco Gauff has been dramatically dethroned at the French Open by Anastasia Potapova, while world number one Aryna Sabalenka has solidified her status as a top contender by reaching the fourth round. The day marked a brutal two days for high-ranked players, following the exits of Jannik Sinner and Novak Djokovic, signaling a potential shift in the balance of power at Roland Garros.Gauff's Struggle on the Red ClayGauff was unable to find her best level on Court Philippe Chatrier, losing 4-6, 7-6(1), 6-4. Despite competing hard, the American struggled to capitalize on crucial points. Anastasia Potapova proved decisive with powerful baseline hitting, breaking to love in the opening game and rattling Gauff with aggressive play. The match was marked by a moment of physical struggle for Gauff, who slipped and fell while reaching a ball, though she recovered to win the next two games before ultimately falling in three sets.Sabalenka's Historic 100th WinIn a contrasting performance, Aryna Sabalenka dispatched Daria Kasatkina 6-0, 7-5 on Court Suzanne Lenglen. This victory was significant not only for the scoreline but for the history books; it marked Sabalenka's 100th win as the world number one, making her only the ninth player in WTA history to achieve this feat. She joins an elite list that includes Martina Navratilova, Steffi Graf, Chris Evert, Serena Williams, Martina Hingis, Monica Seles, Justine Henin, and Iga Swiatek.The New Contenders for the TitleGauff's premature exit leaves Iga Swiatek and Sabalenka as the primary contenders to win the Suzanne Lenglen Cup. Meanwhile, Potapova has emerged as a dangerous dark horse after dishing out a significant upset. The tournament's landscape has shifted dramatically, with the path to the final now seemingly open for the remaining top seeds.Future Outlook: The Swiatek-Sabalenka ShowdownWith the heavy hitters falling, the French Open is shaping up to be a battle between the top two women's players. The focus will now turn to whether Sabalenka can maintain her momentum and whether Swiatek can capitalize on the opportunities presented by the exits of the defending champion and other favorites. Potapova's aggressive style poses a unique challenge for anyone remaining in the draw.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Rise of Nigeria's Digital Herbal Marketplace In Abuja, Nigeria, Oke Bola thought a fertility supplement she found online might help her conceive. Instead, within days of taking it, she struggled to breathe. Her experience reflects a growing online trade in unverified herbal remedies promoted across social media platforms. Bola, who is in her early 40s and has never had children, bought the supplement earlier this year and increased the recommended dosage, hoping for quicker results after hearing about it from friends and family. "I recognised the symptoms of asthma; the wheezing sound at night was familiar," she told Al Jazeera. "When I checked online, I realised it could be from the herbal medication." Her experience is not isolated. Across Nigeria, doctors and pharmacists report a surge in social media-driven self-medication, particularly involving unverified herbal products. This trend is worsening health outcomes, delaying treatment, and adding pressure to an already strained healthcare system serving about 230 million people. Nigeria's young, hyperconnected population increasingly uses digital platforms for health information and advice. But that access has also created what Dr Isaac Kolawole and Dr Fidelis describe as an "algorithmic apothecary" – an unregulated online marketplace where influencers and anonymous sellers promote remedies directly to consumers with little or no scientific backing. Health Impacts of Unverified Herbal Remedies Within this ecosystem, herbal remedies, long part of Nigeria's medical and cultural landscape, are increasingly repackaged as miracle cures, sometimes with dangerous consequences. Doctors report more patients arriving at hospitals only when their conditions have significantly worsened, often after prolonged use of unverified treatments. A consultant nephrologist at the University College Hospital in Ibadan, Dr Yemi Raji, said herbal medicine continues to play a role in kidney disease cases in Nigeria. "When you take herbal medication, you are taking both the good and the bad," he said. "Patients often arrive late, when treatment is more difficult and expensive." Dialysis alone can cost between 50,000 and 100,000 naira ($36-72) per session, several times a week. Studies link herbal use to kidney and liver disease cases across Africa, including findings that about 46 percent of liver disease admissions in one Nigerian hospital involved herbs or roots. A 2022 study found that 76.65 percent of participants had used herbal medicine, with more than a third combining herbal and conventional treatments while 82.44 percent did not inform their doctors. The Algorithmic Amplification Effect On a smartphone screen, relief is just a click away: fertility tonics, eye drops promising restored vision, syrups claiming to "flush out" disease. The advertisements are polished, persuasive and constant, woven into TikTok, Facebook, Instagram and X feeds. "The platforms themselves amplify this effect," said Dr Egemba Chinonso Fidelis, a public health advocate known online as Aproko Doctor. "Their algorithms reward engaging content and push it to wider audiences." Even users who try to avoid such content often encounter it repeatedly, shaped by emotional storytelling, music and urgency-driven messaging. A 2025 Nigeria-based study on Jinja Herbal Mixture found it appeared safe for short-term use within tested dosage ranges, but researchers recorded biochemical changes at higher doses, including altered creatinine and sodium levels in test subjects, signs of possible kidney and liver stress. The study called for further research into long-term effects and interactions with conventional medicines. Regulatory Challenges in the Digital Age The National Agency for Food and Drug Administration and Control (NAFDAC) says it is working to track unregistered manufacturers, but enforcement remains difficult, especially online. "With the sheer volume of products online, enforcement has limited reach," said Isaac Kolawole, the southwest zonal director of NAFDAC. Many sellers use fake or incomplete addresses, making them difficult to trace. NAFDAC requires strict registration, testing and approval before herbal products can be sold or advertised, but regulation has not kept pace with online commerce. Fidelis argued that stronger regulation alone is not enough. "If there are no consequences for lying about healthcare online, people will keep doing it," he said. He noted that scammers have even used AI-generated versions of his image to promote fake products. "Real medicine does not promise to cure everything, and it does not rely on countdowns," he added. "Scammers do." Path Forward for Safer Digital Health As Nigeria's digital economy expands, the intersection of technology and healthcare will only grow more complex. Fidelis stressed that access to affordable healthcare must improve, public trust must be rebuilt, and digital platforms must take responsibility for the health content they amplify. Pharmacist Akinade Akinlolu noted that while conditions like diabetes and hypertension can be managed, online claims often suggest cures. "Economic pressure is also pushing people towards cheaper or 'miracle' alternatives," he added. "Without stronger safeguards," Fidelis warned, "the algorithmic apothecary will continue to grow and put more people at risk." The challenge for Nigeria's healthcare system is to harness the power of digital platforms while ensuring they promote evidence-based care rather than potentially harmful alternatives.